BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 9458075)

  • 21. [Enhanced antitumor effects induced by lymphotactin gene-modified dendritic cells after pulsed with tumor antigen peptide].
    Zhang W; He L; Cao X
    Zhonghua Yi Xue Za Zhi; 1999 Mar; 79(3):170-3. PubMed ID: 11601032
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Embryonic stem cell-derived dendritic cells expressing glypican-3, a recently identified oncofetal antigen, induce protective immunity against highly metastatic mouse melanoma, B16-F10.
    Motomura Y; Senju S; Nakatsura T; Matsuyoshi H; Hirata S; Monji M; Komori H; Fukuma D; Baba H; Nishimura Y
    Cancer Res; 2006 Feb; 66(4):2414-22. PubMed ID: 16489048
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Engineering of highly immunogenic long-lived DC vaccines by antiapoptotic protein gene transfer to enhance cancer vaccine potency.
    Yoshikawa T; Niwa T; Mizuguchi H; Okada N; Nakagawa S
    Gene Ther; 2008 Oct; 15(19):1321-9. PubMed ID: 18480845
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity.
    Liu Y; Huang H; Chen Z; Zong L; Xiang J
    J Gene Med; 2003 Aug; 5(8):668-80. PubMed ID: 12898636
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interleukin-12 and Flt3 ligand differentially promote dendropoiesis in vivo.
    Esche C; Cai Q; Peron JM; Hunter O; Subbotin VM; Lotze MT; Shurin MR
    Eur J Immunol; 2000 Sep; 30(9):2565-75. PubMed ID: 11009090
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A defined serum-free medium useful for monitoring anti-melanoma responses induced by dendritic cell immunotherapy.
    Bouwer AL; Netter P; Kemp RA; McLellan AD
    J Immunol Methods; 2010 Jan; 352(1-2):178-81. PubMed ID: 19903484
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunostimulatory effects of CpG-ODN upon dendritic cell-based immunotherapy in a murine melanoma model.
    Pilon-Thomas S; Li W; Briggs JJ; Djeu J; Mulé JJ; Riker AI
    J Immunother; 2006; 29(4):381-7. PubMed ID: 16799333
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model.
    Schreurs MW; Eggert AA; de Boer AJ; Vissers JL; van Hall T; Offringa R; Figdor CG; Adema GJ
    Cancer Res; 2000 Dec; 60(24):6995-7001. PubMed ID: 11156402
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adenoviral gene transfer of stromal cell-derived factor-1 to murine tumors induces the accumulation of dendritic cells and suppresses tumor growth.
    Fushimi T; O'Connor TP; Crystal RG
    Cancer Res; 2006 Apr; 66(7):3513-22. PubMed ID: 16585175
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination vaccine of dendritic cells (DCs) and T cells effectively suppressed preestablished malignant melanoma in mice.
    Asada H; Kishida T; Hirai H; Shin-Ya M; Imanishi J; Takeuchi M; Mazda O
    Cancer Lett; 2006 Aug; 240(1):83-93. PubMed ID: 16246489
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dendritic cell-derived exosomes stimulate stronger CD8+ CTL responses and antitumor immunity than tumor cell-derived exosomes.
    Hao S; Bai O; Yuan J; Qureshi M; Xiang J
    Cell Mol Immunol; 2006 Jun; 3(3):205-11. PubMed ID: 16893501
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients.
    Davis ID; Chen Q; Morris L; Quirk J; Stanley M; Tavarnesi ML; Parente P; Cavicchiolo T; Hopkins W; Jackson H; Dimopoulos N; Tai TY; MacGregor D; Browning J; Svobodova S; Caron D; Maraskovsky E; Old LJ; Chen W; Cebon J
    J Immunother; 2006; 29(5):499-511. PubMed ID: 16971806
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined alpha tumor necrosis factor gene therapy and engineered dendritic cell vaccine in combating well-established tumors.
    Liu Y; Saxena A; Zheng C; Carlsen S; Xiang J
    J Gene Med; 2004 Aug; 6(8):857-68. PubMed ID: 15293344
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dendritic cells modified to express fractalkine/CX3CL1 in the treatment of preexisting tumors.
    Nukiwa M; Andarini S; Zaini J; Xin H; Kanehira M; Suzuki T; Fukuhara T; Mizuguchi H; Hayakawa T; Saijo Y; Nukiwa T; Kikuchi T
    Eur J Immunol; 2006 Apr; 36(4):1019-27. PubMed ID: 16525992
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Radiotherapy potentiates the therapeutic efficacy of intratumoral dendritic cell administration.
    Teitz-Tennenbaum S; Li Q; Rynkiewicz S; Ito F; Davis MA; McGinn CJ; Chang AE
    Cancer Res; 2003 Dec; 63(23):8466-75. PubMed ID: 14679011
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Melanoma-infiltrating dendritic cells induce protective antitumor responses mediated by T cells.
    Preynat-Seauve O; Contassot E; Schuler P; French LE; Huard B
    Melanoma Res; 2007 Jun; 17(3):169-76. PubMed ID: 17505262
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vaccination with B16 melanoma cells expressing a secreted form of interleukin-1beta induces tumor growth inhibition and an enhanced immunity against the wild-type B16 tumor.
    Björkdahl O; Dohlsten M; Sjögren HO
    Cancer Gene Ther; 2000 Oct; 7(10):1365-74. PubMed ID: 11059695
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FLT3 ligand administration after hematopoietic cell transplantation increases circulating dendritic cell precursors that can be activated by CpG oligodeoxynucleotides to enhance T-cell and natural killer cell function.
    Chen W; Chan AS; Dawson AJ; Liang X; Blazar BR; Miller JS
    Biol Blood Marrow Transplant; 2005 Jan; 11(1):23-34. PubMed ID: 15625541
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma.
    Tatsumi T; Takehara T; Kanto T; Miyagi T; Kuzushita N; Sugimoto Y; Jinushi M; Kasahara A; Sasaki Y; Hori M; Hayashi N
    Cancer Res; 2001 Oct; 61(20):7563-7. PubMed ID: 11606395
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Feasibility of using hepatitis B virus surface antigen as target antigen in immunogen therapy against cancer].
    Qiu S; Ye S; Tang Z; Qian S; Li L
    Zhonghua Yi Xue Za Zhi; 2002 Feb; 82(4):253-6. PubMed ID: 11953174
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.